VBVinod P. Balachandran

Vinod P. Balachandran

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Vinod P. Balachandran has a total of 679 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    An information-theoretic framework for inferring T cell dynamics from single-cell RNA and T cell receptor sequencing

    by Nicholas Ceglia, Sohrab Salehi, Zachary M. Sethna, Yuval Elhanati, Samuel S. Freeman, Olga Lyudovyk, Bharat Burman, Andrew Chow, Dmitriy Zamarin, Susan DeWolf, et al.

    Single-cell T cell receptor (TCR) repertoire sequencing enables simultaneous profiling of gene expression and TCR sequences, providing a coregistered measure of T cell phenotypic diversity and clonal dynamics. However, principled probabilistic frameworks for joint modeling of clonotype and phenotype have remained limited. Here we introduce TCRi, a hierarchical Bayesian information-theoretic framework that infers the joint probability distribution between genetic clonotype and transcriptional phenotype from paired single-cell transcriptomic and TCR sequencing data. TCRi treats phenotype assignment as a probabilistic inference problem: a variational autoencoder embeds single-cell expression into a structured latent space, and a hierarchical Bayesian model learns clonotype-specific phenotype distributions through principled information-sharing across clonotypes, patients and covariates. From these distributions, TCRi computes information-theoretic quantities: clonotypic entropy, phenotypic entropy, phenotypic flux and mutual information between clonotype and phenotype. When TCRi was applied to four real-world datasets comprising 167,118 CD8 T cells from patients with cancer treated with anti-PD-(L)1 immune checkpoint blockade, mutual information emerged as a robust discriminator of therapeutic response.

  • The neoantigen quality model: Is closer to self more non-self?

    by Vinod P. Balachandran, Zachary Sethna, Benjamin D. Greenbaum

  • Technical Complications and Salvage of Hepatic Artery Infusion Pumps

    by Omar A. Zaki, Lauren E. Schleimer, Hannah L. Kalvin, Ankur Choubey, Ahmad B. Barekzai, Joslyn Jung, Misha Armstrong, Remo Alessandris, Merve Rousian, Ruben Geevarghese, et al.

    Objective: Describe the technical complications of hepatic artery infusion pump (HAIP) placement and characterize salvage rates. Summary Background Data: HAIP chemotherapy is an effective tool used in the treatment of hepatic malignancies and has become increasingly adopted at select centers. Much of the safety data is reported from small, newer programs or older, large series. Methods: Retrospective analysis of all patients who underwent HAIP placement at our institution between 2000 and 2022 was conducted. Pump salvage was defined as the ability to receive HAIP chemotherapy after a pump-associated complication. Pump failure was defined as an HAIP-related complication permanently stopping ongoing HAIP chemotherapy. Results: Over the study period, 2935 patients had an HAIP placed for colorectal liver metastases (n=2582, 88%), intrahepatic cholangiocarcinoma (n=294, 10%) or another malignancy (n=59, 2%). Of all patients, 759 (26%) had an HAIP-related complication, with 404/759 (53%) having their pump salvaged. The most common complications were abnormal perfusion (n=360 [12%], 285/360 [79%] salvaged), arterial pseudoaneurysm and/or hemorrhage (n=117 [4%], 7/117 [6%] salvaged), and pump-pocket infection (n=115 [4%], 60/115 [52%] salvaged). The complications with the highest salvage rates were pump-pocket seroma (n=15/16, 94%), pump-flipping (n=41/44, 93%), and pump-pocket hematoma (n=45/49, 92%). Unsalvaged complications were catheter dislodgement from vessel (n=0/47, 0%), catheter erosion into bowel (n=0/25, 0%), and arterial thrombosis (n=0/19, 0%). The cumulative incidence of pump failure at 1 year in patients receiving adjuvant therapy was 6.6%, and 4.5% among those receiving palliative therapy. Conclusions: HAIP-related complications occur in about one quarter of patients, predominantly perfusion and pump-pocket complications. These are salvageable in the majority of cases with multidisciplinary interventions.

  • Recurrence Patterns of Resected Ampullary Adenocarcinoma and Implications for Multimodal Therapy: A Hidden Genome–Derived Analysis from the Ampullary Cancer Collaborative

    by Brett L. Ecker, Kenneth Seier, Ankur Choubey, Austin M. Eckhoff, Gabriella N. Tortorello, Vinod P. Balachandran, Nicola Blackburn, Michael I. D’ANgelica, Matthew P. Deek, Ronald P. DeMatteo, et al.

  • Beyond Survival

    by Ankur P. Choubey, Julie Leal, Charlie White, Kevin C. Soares, Lily V. Saadat, Alice C. Wei, T. Peter Kingham, Vinod P. Balachandran, Jeffrey A. Drebin, William R. Jarnagin, et al.

    Objective: Describe the long-term health-related quality of life (HR-QoL) after curative-intent hepatectomy for high-risk colorectal liver metastases (CRLM). Methods: This prospective study enrolled patients with resectable CRLM with clinical risk score ≥3. European Organization for Research and Treatment of Cancer QLQ-C30, LMC21, and EuroQol EQ-5D-5L were administered at preoperative and postoperative visits, and at 6, 12, 18, 24, and 36 months from hepatectomy, and cancer disease state was recorded. Linear mixed models were used to examine the trajectory of HR-QoL scores. Results: From 297 consented, 146 were evaluable by completing preoperative and postoperative surveys. Median age was 52 years, 42% (n=61) were female, and 70% (n=102) had synchronous CRLM. The QLQ-C30 summary score decreased by −14.6 points (95% CI: −17.2, −12.0) from baseline at the postoperative survey ( P P P P =0.029). Patients with recurrence had similar EQ-VAS scores as baseline at 12 months but remained lower than NED patients at each timepoint after the postoperative survey (all P <0.05). Conclusions: HR-QoL decreases postoperatively before returning to preoperative levels and exceeding it among patients without recurrence. Cancer recurrence significantly influenced HR-QoL.

  • ASO Visual Abstract: Investigating Age-Related Differences in Survival Outcomes and Mutation Status in Patients with Intrahepatic Cholangiocarcinoma

    by Misha Armstrong, Hannah Kalvin, Mithat Gönen, Ghassan Abou-Alfa, Vinod P. Balachandran, Andrea Cercek, Michael I. D’ANgelica, James Harding, T. Peter Kingham, Eileen O’REilly, et al.

  • Investigating Age-Related Differences in Survival Outcomes and Mutation Status of Patients with Intrahepatic Cholangiocarcinoma

    by Misha Armstrong, Hannah Kalvin, Mithat Gönen, Ghassan Abou-Alfa, Vinod P. Balachandran, Andrea Cercek, Michael I. D’ANgelica, James Harding, T. Peter Kingham, Eileen O’REilly, et al.

    Survival outcomes for intrahepatic cholangiocarcinoma (IHC) remain poor due to late-stage presentation and limited effective treatment options. Previous st

  • Top Cited Papers

    Pancreatic cancer

    by Susanne Roth, Minoti Apte, Vinod P. Balachandran, Giulia Biffi, Thierry Conroy, Edna Cukierman, Efrat Dotan, Irene Esposito, Barbara T. Grünwald, Miriam Klauß, et al.

    Pancreatic ductal adenocarcinoma remains one of the deadliest malignancies, characterized by late diagnosis, aggressive biology and limited therapeutic success. Advances in multiagent chemotherapy have improved outcomes across disease stages, whereas precision medicine approaches are reshaping treatment paradigms. Personalized RNA vaccines and oncogenic KRAS-directed agents represent emerging immunological and molecular frontiers. Multimodal treatment regimens and surgical innovations, including vessel-oriented and minimally invasive techniques, have enhanced complete resection rates and enabled conversion of initially unresectable locally advanced pancreatic cancer into resectable disease. Increasingly, multidisciplinary, biology-guided strategies define resectability and the sequence of systemic and local therapies. The tumour microenvironment’s complex stromal and immune ecology remains central to therapeutic resistance but also offers opportunities for rational combination therapy. Early detection and risk-adapted surveillance for high-risk individuals are advancing, as are artificial intelligence-assisted imaging and liquid biopsy approaches. Despite persistent challenges, the convergence of mechanistic insights, precision therapeutics and supportive care provides a framework for transforming pancreatic ductal adenocarcinoma from an inevitably lethal disease towards a better manageable condition.


  • Top Cited Papers
    Open Access

    Pembrolizumab and olaparib in homologous-recombination-deficient metastatic pancreatic cancer: the phase 2 POLAR trial

    by Wungki Park, Catherine A. O’COnnor, Joanne F. Chou, Marc Hilmi, Zeynep Tarcan, Carly Schwartz, Mary Larsen, Ramzi Homsi, Karthigayini Sivaprakasam, Shigeaki Umeda, et al.

    Homologous recombination deficiency (HRD) arising from BRCA1 or BRCA2 or PALB2 mutations confers sensitivity to platinum chemotherapy and PARP inhibition in pancreatic cancer (PC) and may enable prolonged disease control with immune checkpoint blockade (ICB). The phase 2 POLAR trial evaluated maintenance pembrolizumab plus olaparib following platinum-based chemotherapy in biomarker-stratified metastatic PC. Sixty-three participants were enrolled into three cohorts: cohort A ( BRCA1 / BRCA2 -mutated or PALB2 -mutated HRD, n = 33), cohort B (non-core HRD, n = 15) and cohort C (platinum sensitive, HRD-wild type, n = 15). Cohort A used a two-stage design with co-primary endpoints of at least 43% Response Evaluation Criteria in Solid Tumors (RECIST) objective response rate (ORR) and at least 77% 6-month progression-free survival (PFS) rate. Among RECIST-evaluable participants in cohort A ( n = 20), ORR was 35% (95% confidence interval (CI): 15−59%), whereas 6-month PFS rate in the full cohort ( n = 33) was 64% (95% CI: 49−82%), not meeting the primary endpoint. At a median follow-up of 37 months (95% CI: 27−47), median PFS and overall survival (OS) for cohort A were 8.3 (95% CI: 5.3−not reached (NR)) and 28 (95% CI: 12−NR) months, with 2-year and 3-year OS rates of 56% (95% CI: 41−76%) and 44% (95% CI: 28−69%), respectively. In cohorts B and C, ORR was 8% (95% CI: 0−38%) and 14% (95% CI: 2%-43%); median PFS was 4.8 (95% CI: 4.0−12) and 3.3 (95% CI: 1.9−4.8) months; and median OS was 18 (95% CI: 13−NR) and 10 (95% CI: 8.9−24) months, respectively. Preplanned translational analyses showed that circulating tumor DNA response, increased tumor-infiltrating lymphocytes and enrichment of frameshift indel neoantigens were associated with durable clinical benefit. These data suggest that a subset of HRD PC may derive prolonged benefit from PARP-ICB maintenance and support further development of biomarker-guided precision immunotherapy strategies in PC. ClinicalTrials.gov identifier: NCT04666740 .


  • Open Access

    POLQ-driven repair scars shape the immunogenic landscape of homologous recombination-deficient pancreatic cancer

    by Wungki Park, Shigeaki Umeda, Marc Hilmi, Catherine O’COnnor, Roshan Sharma, Nuray Tezcan, Haochen Zhang, Yingjie Zhu, Carly Schwartz, Amin Yaqubie, et al.

    Pancreatic cancer (PC) is broadly resistant to immune checkpoint blockade, although a subset of homologous recombination-deficient (HRD) tumors exhibits durable immune engagement. The genomic features that distinguish these immune-responsive tumors from immune-inert HRD tumors remain poorly understood. Here we identify a microhomology-mediated end joining (MMEJ) repair scar, the MMEJ Deletion Footprint (MDF), as a genomic readout of POLQ-associated error-prone repair that enriches for frameshift indels. Across the multi-omic discovery cohort integrating tumor genomics, single-nucleus transcriptomics and spatial immune profiling, MDF-high HRD PC exhibited increased frameshift-indel-derived neoantigens and interferon programs. MDF was further associated with remodeling of the myeloid compartment toward MHC II-high dendritic cell-like antigen-presenting macrophage states and the immune synapse architecture marked by increased spatial interaction between APC-like macrophages and cytotoxic CD8 + T cells. These tissue-level features aligned with a functional trajectory shift of CD8 + T cells, consistent with effective anti-tumor immunity and was associated with favorable clinical outcomes of patients. Together, our findings position MMEJ-linked repair scarring as actionable biology that connects an HRD genotype to immune organization and suggests rational immunotherapy combinations that may enhance antigen presentation and myeloid activation to extend durable benefit in HRD-lineage cancers.